Efficient, scanner-agnostic WSI sharing, with workflow optimized viewer
Secure image database solutions deployable on-premises or in the cloud
Automated cytopathology supported by explainable AI models
Accurate, operator-independent marker indexes embedded in the viewer
Building on more than 30 years of expertise in digital cell imaging, IMSTAR was restructured in 2025, leading to the creation of two Companies: Diomedes managed by IMSTAR R&D team to maintain and upgrade software solutions, developed by IMSTAR, and FMS Medtech managed by the IMSTAR Scientific and Management team, to drive Diomedes Business development, Marketing and Sales.
Computer-Aided Quantitative Image Analysis of Multiple Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Assays in Breast Carcinoma. Accepted, Jan 2026 at the Arch. Pathol. Lab. Med.
Dabbs DJ., Torlakovic E., Nielsen S., Parry SC., Yu J., Stoos C., Clark B., Høeg H., Thagaard J., Sompuram SR., Naber SP., Yagi Y., Sayre J., Vani K., Cossutta M., Soussaline F., Papine A., t'Hart NA., Szabolcs MJ., Jasani B., Kinloch M., Chiriboga L., Miller K., Bogen S.
New standards in HER2-low testing: the CASI-01 comparative methods study.
EBioMedicine 2025;120:105919
Contact us to learn more about our solutions and partnerships.